Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Non-Current Debt (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Non-Current Debt for 6 consecutive years, with $10.2 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Non-Current Debt fell 39.65% year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Sep 2019, down 39.65%, and an annual FY2018 reading of $15.2 million, down 24.08% over the prior year.
  • Non-Current Debt was $10.2 million for Q3 2019 at Larimar Therapeutics, down from $11.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $20.2 million in Q1 2018 and bottomed at $1.2 million in Q3 2016.
  • Average Non-Current Debt over 5 years is $10.0 million, with a median of $10.2 million recorded in 2019.
  • The sharpest move saw Non-Current Debt plummeted 71.17% in 2016, then decreased 24.08% in 2018.
  • Year by year, Non-Current Debt stood at $3.5 million in 2015, then crashed by 65.25% to $1.2 million in 2016, then skyrocketed by 1566.67% to $20.0 million in 2017, then dropped by 24.08% to $15.2 million in 2018, then tumbled by 33.05% to $10.2 million in 2019.
  • Business Quant data shows Non-Current Debt for LRMR at $10.2 million in Q3 2019, $11.9 million in Q2 2019, and $13.5 million in Q1 2019.